Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
RESEARCH TOOLSreports
Liquidia Technologies (LQDA) Stock Price & Analysis
439 Followers
LQDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.71 - $16.99
Previous Close$11.63
Volume436.07K
Average Volume (3M)805.54K
Market Cap
$888.69M
Enterprise Value$730.83M
Total Cash (Recent Filing)$157.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 08, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding76,382,718
10 Day Avg. Volume863,399
30 Day Avg. Volume805,540
Standard Deviation0.21
R-Squared0.00377
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)11.80
Price to Sales (P/S)205.66
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue45.77
Enterprise Value/Gross Profit50.06
Enterprise Value/Ebitda-7.46
Forecast
1Y Price Target
$27.20Price Target Upside133.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Liquidia Technologies News
Bulls Say, Bears Say
Bulls Say
Market OpportunityUpon FDA approval, LQDA expects Yutrepia to address a $3B market opportunity as an alternative to treprostinil therapies in PAH and PH-ILD.
Market PositioningYutrepia's clear differentiation is seen as a key driver in gaining market share upon launch.
Regulatory ApprovalThere do not appear to be any legal barriers preventing the FDA from approving Yutrepia for pulmonary arterial hypertension (PAH).
Bears Say
Lack Of GuidanceLiquidia is unable to provide guidance or an update on expected timing for the approval.
Legal ChallengesUTHR has made it clear they would exhaust all legal avenues to prevent the FDA approval and/or launch of LQDA's product.
Regulatory UncertaintyDespite the removal of legal barriers, Yutrepia has not yet been approved.
---
Ownership Overview
78.61% Insiders
6.39% Mutual Funds
9.17% Other Institutional Investors
5.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $5.71 and its highest was $16.99 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Currently, no data Available
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Aug 08, 2024 which is in 11 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on May 14, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.324 by -$0.216.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -$0.34.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 76,413,830 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.324. Following the earnings report the stock price went up 2.759%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Among the largest hedge funds holding Liquidia Technologies Inc’s share is Farallon Capital Management, L.L.C.. It holds Liquidia Technologies Inc’s shares valued at 30M.
---
Liquidia Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.20 (133.88% Upside)
$27.20 (133.88% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.84%
12-Months-Change
Fundamentals
Return on Equity
-128.27%
Trailing 12-Months
Asset Growth
52.90%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
---
LQDA Earnings Call
Q1 2024
0:00 / 0:00
---
LQDA Stock 12 Month Forecast
Average Price Target
$27.20
▲(133.88% Upside)
Technical Analysis
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+42.86%
assigned a buy rating 3 months ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +42.86% per trade.
---